Drug Trial Radar · NCT07816237
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Bisirna Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria, PNH
Interventions
VSA012Drug
VSA012 Injection
Eculizumab (Soliris®)Drug
Eculizumab injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with sustained hemoglobin levels ≥ 120 g/L among those without RBC transfusion (defined as no red blood cell infusion after W2 to W26).Time frame: between Week 2 and Week 26
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Jilin
Jilin City, Changchun, China
Quanzhou
Quanzhou, Fujian, China
Guangzhou
Guangzhou, Guangdong, China
Nanning
Nanning, Guangxi, China
Ha'erbin
Harbin, Heilongjiang, China
Zhengzhou
Zhengzhou, Henan, China
Wuhan
Wuhan, Hubei, China
Changsha
Changsha, Hunan, China
Nantong
Nantong, Jiangsu, China
Xi'an
Xi’an, Shanxi, China
Chengdu
Chengdu, Sichuan, China
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.